US 12,102,649 B2
Methods and compositions for treating endometriosis
Thomas K. Equels, Ocala, FL (US); and David R. Strayer, Bryn Mawr, PA (US)
Assigned to AIM ImmunoTech Inc., Ocala, FL (US)
Appl. No. 17/769,986
Filed by AIM ImmunoTech Inc., Ocala, FL (US)
PCT Filed Oct. 22, 2020, PCT No. PCT/US2020/056882
§ 371(c)(1), (2) Date Apr. 18, 2022,
PCT Pub. No. WO2021/081218, PCT Pub. Date Apr. 29, 2021.
Claims priority of provisional application 63/065,475, filed on Aug. 13, 2020.
Claims priority of provisional application 63/065,476, filed on Aug. 13, 2020.
Claims priority of provisional application 62/931,098, filed on Nov. 5, 2019.
Claims priority of provisional application 62/924,591, filed on Oct. 22, 2019.
Prior Publication US 2022/0387475 A1, Dec. 8, 2022
Int. Cl. A61K 31/7105 (2006.01); A61K 9/00 (2006.01); A61K 31/713 (2006.01); A61K 35/17 (2015.01); A61P 15/00 (2006.01)
CPC A61K 31/7105 (2013.01) [A61K 9/0024 (2013.01); A61K 35/17 (2013.01); A61P 15/00 (2018.01); A61K 31/713 (2013.01)] 19 Claims
 
1. A method for treating endometriosis or ameliorating a symptom of endometriosis in a subject comprising
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic double stranded RNA (tdsRNA);
wherein the tdsRNA is selected from the group consisting of
rIn·r(CxU)n; and
rugged dsRNA;
wherein x is one or more selected from the group consisting of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 4-29, 11-14, and 30-35, wherein n is from 40-40,000.